Rapid Detection of Triazole Antifungal Resistance in Aspergillus fumigatus
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Triazole resistance in Aspergillus fumigatus is an uncommon but rising phenomenon. Susceptibility testing is rarely performed and can take 48 h or longer, which is an impediment to effective therapy. Molecular diagnostic probing of well-defined resistance mechanisms, which serve as surrogate markers, provides an alternative approach to rapidly (within hours) and efficiently identify resistant strains. The mechanisms of triazole resistance in A. fumigatus are limited to amino acid substitutions in the drug target Cyp51A and include amino acid substitutions at the positions Gly 54, Gly 138, Met 220, and Leu 98, coupled with a tandem repetition in the gene promoter. We report the development of a real-time PCR assay utilizing molecular beacons to assess triazole resistance markers in A. fumigatus . When combined in a multiplex platform, the assay provides a comprehensive evaluation of drug resistance in A. fumigatus .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Aspergillus fumigatus and Aspergillosis
Latgé, J.-P. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.310 · Cited by 2,307 · cited 1×
“Hence, IA is still associated with a high mortality rate that ranges from 30 to 90% (4, 7, 20, 21, 30, 43).”
BackgroundAspergillus fumigatus and Aspergillosis in 2019
Latgé, J.-P., & Chamilos, G. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00140-18 · Cited by 1,400
Mellado, E., Garcia-Effron, G., Alcázar-Fuoli, L., Melchers, W. J. G., Verweij, P. E., Cuenca-Estrella, M., & Rodríguez-Tudela, J. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01092-06 · Cited by 490 · cited 4×
“However, when coupled with a 34-bp TR in the promoter of cyp51A, the dual mutant displays cross-resistance to multiple triazole drugs (except PSC) ( 29 , 44) (Fig. 2B).”
BackgroundInfluentialSelf-citationInvasive Aspergillosis: Epidemiology, Diagnosis and Management in Immunocompromised Patients
Maschmeyer, G., Haas, A., & Cornely, O. A. (2007) · Drugs · doi:10.2165/00003495-200767110-00004 · Cited by 366
Mellado, E., Diaz-Guerra, T. M., Cuenca-Estrella, M., & Rodriguez-Tudela, J. L. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.7.2431-2438.2001 · Cited by 307
Self-citationDiaz-Guerra, T. M., Mellado, E., Cuenca-Estrella, M., & Rodriguez-Tudela, J. L. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.1120-1124.2003 · Cited by 281
Self-citationBalashov, S. V., Park, S., & Perlin, D. S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01653-05 · Cited by 225
Self-citationMellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Cuenca-Estrella, M., & Rodriguez-Tudela, J. L. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2747-2750.2004 · Cited by 210
Self-citationSlaven, J. W., Anderson, M. J., Sanglard, D., Dixon, G. K., Bille, J., Roberts, I. S., & Denning, D. W. (2002) · Fungal Genetics and Biology · doi:10.1016/s1087-1845(02)00016-6 · Cited by 202 · cited 1×
“However, such mechanisms have rarely been described in clinical isolates, although they have been reported in laboratory mutants (33, 40 ).”
BackgroundPetrikkou, E., Rodrı́guez-Tudela, J. L., Cuenca-Estrella, M., Gómez, A., Molleja, A., & Mellado, E. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.4.1345-1347.2001 · Cited by 134 · cited 1×
“reference method (34), with modifications (5, 36, 38).”
MethodSelf-citationRodriguez-Tudela, J. L., Chryssanthou, E., Petrikkou, E., Mosquera, J., Denning, D. W., & Cuenca-Estrella, M. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.11.5236-5237.2003 · Cited by 79
Cited by
Efflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
Sanglard, D., Coste, A., & Ferrari, S. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00578.x · Cited by 285
“In contrast, mutations at position M220 confer itraconazole resistance and also high MICs to voriconazole or posaconazole (Garcia-Effron et al., 2008a).”
BackgroundUpdate on antifungal resistance in Aspergillus and Candida
Arendrup, M. C. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12513 · Cited by 240
Treatment of Chronic Pulmonary Aspergillosis: Current Standards and Future Perspectives
Alastruey-Izquierdo, A., Cadranel, J., Flick, H., Godet, C., Hennequin, C., Hoenigl, M., Kosmidis, C., Lange, C., Munteanu, O., Page, I., et al. (2018) · Respiration · doi:10.1159/000489474 · Cited by 126
Dudakova, A., Spiess, B., Tangwattanachuleeporn, M., Sasse, C., Buchheidt, D., Weig, M., Groß, U., & Bader, O. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00095-16 · Cited by 113
Metadata
- Authors
- Garcia-Effron, G., Dilger, A., Alcazar-Fuoli, L., Park, S., Mellado, E., & Perlin, D. S.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2008-04
- Volume
- 46
- Issue
- 4
- Pages
- 1200-1206
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2164919014
- Cited by
- 101
- References
- 12
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.